Loading…
Loading…
This biotech innovator in monoclonal antibody therapies reported a notable insider sale amid ongoing clinical-stage developments.
Arjun Agarwal sold 10,290 shares for a transaction value of approximately ~$608,000, based on a weighted average price of $59.07 per share on May 18, 2026. This sale represented 38.5% of Agarwal's direct holdings, reducing direct ownership from 26,696 to 16,406 shares.
Oruka Therapeutics, Inc. (ORKA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
The mean of analysts' price targets for Oruka Therapeutics, Inc. (ORKA) points to an 111.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
This clinical-stage biotech focused on antibody therapies for immunological disorders reported a notable insider sale in its latest filing.
MENLO PARK, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced its presentation at the 2026 Jefferies Global Healthcare Conference, taking place in New York, NY from June 2-4, 2026.
ORKA-001 EVERLAST-A 16-week data showed 63.5% PASI 100 rate and a favorable tolerability profile, with longer-term data expected in 2H 2026
This clinical-stage biotech develops monoclonal antibody therapies targeting psoriasis and other immunology indications.
No recent filings indexed.
Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.
Click below to see what's inside, then upgrade to read every transcript for ORKA and 80,000+ other tickers.
Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.